5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors

C. Filì;1 M. Gobbi;2 G. Martinelli;3 C. Finelli;4 I. Iacobucci;5 E. Ottaviani;5 L. Cocco;6 M. Follo;6 A. Candoni;7 E. Simeone;DAMIANI, Daniela;TIRIBELLI, Mario;7 M. Miglino;2 F. Lauria;8 M. Bocchia;8 M. Defina;8 C. Clissa;9 C. Skert;10 C. Bergonzi;10 M. Malagola;10 A. Peli;10 A. Turra;10 F. Cattina;10 C. Colombi;10 D. Russo10

2010-01-01